Jaguar Health, INC 10-Q quarterly reports

Jaguar Health Inc. reported a significant increase in revenue for Q1 2026, primarily driven by a new licensing agreement, while managing operating expenses and advancing its pipeline.

Jaguar Health reports increased net losses and negative cash flows for Q3 2025, raising substantial doubt about its ability to continue as a going concern despite progress in clinical trials and product launches.

Jaguar Health reported increased net losses and a significant decrease in cash for Q2 2025, despite slight revenue growth, as it continues to fund product development and commercialization efforts.

Jaguar Health's Q1 2025 results reveal a revenue decrease alongside ongoing efforts in clinical development and commercial expansion.

Jaguar Health's Q3 2024 results show a revenue increase driven by Mytesi sales, but the company continues to experience significant losses.

Jaguar Health's second quarter 2024 results show a net loss, but also highlight progress in clinical trials and commercialization efforts.

Jaguar Health's first quarter 2024 results reveal continued operating losses, though the company is making progress in its clinical programs and strategic partnerships.